The team

Dr Ben Shaw


Ben completed his undergraduate degree in Biological Sciences at the University of Oxford. He was then accepted onto the prestigious Wellcome Trust PhD Studentship for Developmental Biology at the University of Cambridge. 

Ben joined SwiftDx in 2015 and has successfully lead it through a series of funding rounds and developmental milestones. In addition to his business development role, Ben continues to help push the science in the company to its full potential. Ben’s deep understanding of the science allows him to effectively communicate its potential to both potential customers and investors.

Dr Gustavo Cerda-Moya


Gus completed his PhD at the University of Cambridge in the field of molecular biology. He then went on to do a successful post-doctoral position also at the University of Cambridge. Using his knowledge of molecular biology, he discovered a revolutionary method of detecting DNA on a lateral flow device. 

Gus formed the company when he submitted the first patent in 2015 and has worked with the company since then. Gus has been leading the scientific development within the company since its creation and has spearheaded the innovations and product development within the company.

Andrew Taylor

Non-Executive Director

Andrew is a Big Four trained Chartered Accountant who has worked with privately owned UK businesses, one of the largest FTSE 100 companies and as CFO of a main market listed PLC.

Since 2011 Andrew has been working as a portfolio FD supporting small and medium sized companies in Cambridge. He has provided numerous clients across diverse industries (including BioTech, Tech, manufacturing and SAAS) with varying levels of support as either a part-time FD or NED

Sam Hussain

Non-Executive Director

Sam is a former management consultant who is now working with early-stage start-ups.

After graduating with a Masters in Engineering from Oxford, he spent three and a half years as a consultant at Oliver Wyman. While he was there, he worked on strategy projects including writing business cases, financial modelling, market entry strategies and assessing growth and M&A opportunities. He has worked for a range of corporates and investment funds in the UK, Europe and Middle East. Sam now operates as a key member of the team, helping produce business models and financial forecasts.

Barry Burles

Non-Executive Director

Barry has developed many medical diagnostic and imaging companies from an early stage. He brings experience to the SwiftDx team and provides mentorship and introductions to move this exciting company forward. 

Barry was the Group Executive for Corporate Strategy and Research at Dalgety plc, the largest food and agriscience company in the UK. He was invited to work for the NHS Innovation Health and Wealth initiative, encouraging the Hospital Trusts and Clinical Commissioning Groups to adopt bolder approaches to innovation. He is ideally placed to guide this passionate team to business success.

Advisory Board

Richard Allan

Scientific Advisory Board Member

Richard Allan is a qualified tropical parasitologist and has over 30 years’ experience as a public health manager. Following four years in primary health care development for Zaire through the mid-1980s he spent four years in malaria treatment research with Oxford University and the Medical Research Council with programmes in Gambia and Sierra Leone. Since the start of the Rwanda crisis in 1994 Richard has dedicated his efforts to developing disease control initiatives in conflict-based emergencies and natural disasters working with OXFAM, Tearfund and MERLIN.

Richard was the Roll Back Malaria coordinator for complex emergencies with the Global Secretariat (early 2000 to late 2002) at the World Health Organisation where he established and managed the cross-sectoral partnerships that resulted in the development of important new disease control tools and strategies for malaria control.  Richard is currently CEO of the MENTOR Initiative.

Professor Anne Ferguson-Smith

Scientific Advisor

Professor Anne Ferguson-Smith is the Pro-Vice-Chancellor for Research and International Partnerships at the University of Cambridge. She is the Arthur Balfour Professor of Genetics and a former head of the Department of Genetics. In addition to her roles at Cambridge, she is President of the Genetics Society, is a member of the UKRI BBSRC Council, was elected to EMBO in 2006, to the UK Academy of Medical Sciences in 2012, became a Fellow of the Royal Society in 2017 and received her Ph.D. from the Department of Biology at Yale University.

A molecular geneticist, with a background in epigenetics and functional genomics, her research has utilised a wide range of approaches to study developmental and physiological pathways in health and disease.